OKYO Pharma Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $74.0M
- Price
- $1.41
- % Change (Daily % change from the live per-ticker quote feed.)
- -3.42%
- Volume
- 33.7K
About
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Quick stats
Shares outstanding52.5M
Computed float—
Float / sharesUnknown
Cash runway (months)35.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001849296
Websitehttps://www.okyopharma.com
AI Summary
AI-generated1/31
standardbullishclinical trial
OKYO Pharma Announces First Patients Enrolled in Phase 3 Pivotal Trial of Urcosimod for Neuropathic Corneal Pain
OKYO Pharma enrolled its first patients in the Phase 3 NEPTUNE trial of urcosimod, its lead candidate and a potential first-in-class treatment for neuropathic corneal pain.
The first patients were dosed by Dr. Melissa Toyos at Toyos Clinic in Nashville, TN, with additional site activations expanding across U.S. and European centers, including Italy, Spain and France.
The multicenter, registrational study follows FDA guidance, dosing patients 4 drops per day for 12 weeks with a primary endpoint of change in ocular pain via VAS score.
NCP currently has no FDA-approved treatment, leaving a significant unmet need if urcosimod proves effective.
Red flags
- early-stage milestone with no data readout; trial execution and enrollment pace still uncertain